Loading…
Bright Minds Biosciences Inc. is projected to rise to $107.89 by 2027, a +24% move from its current price of $87.04. DRUG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $84.53 | $87.10 | $89.75 | +0.06% |
| May 30 | $83.54 | $87.15 | $90.92 | +0.13% |
| May 31 | $82.80 | $87.21 | $91.85 | +0.19% |
| Jun 1 | $82.19 | $87.27 | $92.65 | +0.26% |
| Jun 2 | $81.66 | $87.32 | $93.37 | +0.32% |
| Jun 3 | $81.20 | $87.38 | $94.03 | +0.39% |
| Jun 4 | $80.77 | $87.43 | $94.65 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $80.77 | $87.43 | $94.65 | +0.45% |
| Week 2 | $78.52 | $87.83 | $98.25 | +0.91% |
| Week 3 | $76.91 | $88.23 | $101.21 | +1.37% |
| Week 4 | $75.64 | $88.63 | $103.86 | +1.83% |
| Week 5 | $74.57 | $89.03 | $106.30 | +2.29% |
| Week 6 | $73.65 | $89.44 | $108.60 | +2.75% |
| Week 7 | $72.84 | $89.84 | $110.81 | +3.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bright Minds Biosciences Inc. is a biotechnology company that develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders.
The company also advances BMB-101, which has completed phase 1 trial for an undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. It also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc.
has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study.
The company was founded in 2017 and is headquartered in New York, New York.
Bright Minds Biosciences Inc. (DRUG) is a biotechnology company with a current price of $83.50 and a market cap of $817.23M. It is ranked 2677 by market capitalization.
The near-term forecast for 2026 shows min $68.45, avg $83.50, max $118.67, with an ROI of 0 and neutral sentiment.
The longer-term forecast paints a bullish path, with rising averages across years: 2027 avg $102.54, 2028 avg $120.74, 2029 avg $131.89, 2030 avg $178.96, 2040 avg $446.01, 2050 avg $1,082.02. The maximums reach $139.64 in 2027, $268.71 in 2030, $788.52 in 2040, and $2,108.87 in 2050, with corresponding ROI values of 22.8, 114.3, 434.1, and 1195.8. Sentiment remains bullish across much of the forecast horizon.
A major floor 22.0% below — a decisive break under it would weaken the trend.
The nearest floor, 14.4% below — buyers have tended to step in here.
The nearest ceiling, 4.3% above — a clean break opens room to run.
A major ceiling 15.3% above — clearing it would confirm fresh momentum.
Key DRUG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DRUG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $84.57 | Buy | $84.44 | Buy |
| MA 10 | $81.21 | Buy | $83.39 | Buy |
| MA 20 | $84.00 | Buy | $83.53 | Buy |
| MA 50 | $81.69 | Buy | $82.74 | Buy |
| MA 100 | $82.05 | Buy | $79.52 | Buy |
| MA 200 | $70.63 | Buy | $70.37 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.72 | Neutral |
| Stoch RSI (14) | 97.37 | Sell |
| CCI (20) | 58.65 | Neutral |
| Williams %R (14) | -12.43 | Info |
| MACD (12,26,9) | 0.26 | Buy |
| ROC (12) | 1.80 | Buy |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 87.57 | Sell |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | -1.24 | Sell |
| Ultimate (7,14,28) | 66.59 | Neutral |
| Momentum (10) | 2.39 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 87.53 | Sell |
| ADX (14) | 14.82 | Neutral |
| ATR (14) | 2.02 | Info |
The 30-day technical picture is bullish overall. RSI14 is 50, with the short-term trend supported by SMA50 at $81.13 and SMA200 at $70.13.
Key support and resistance levels are $74.54 and $90.79, respectively, shaping the near-term risk/reward.
The 30-day range lies between $67.97 and $102.57, outlining the near-term volatility window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $68.45 | $87.04 | $123.71 | 0% | Neutral | |
| $84.76 | $107.89 | $145.96 | +24% | Bullish | |
| $98.08 | $128.66 | $180.91 | +48% | Bullish | |
| $105.31 | $141.68 | $205.37 | +63% | Bullish | |
| $139.30 | $191.66 | $285.07 | +120% | Bullish | |
| $162.77 | $228.62 | $347.78 | +163% | Bullish | |
| $165.17 | $236.50 | $367.09 | +172% | Bullish | |
| $189.17 | $275.81 | $436.01 | +217% | Bullish | |
| $190.15 | $282.07 | $453.48 | +224% | Bullish | |
| $192.67 | $290.58 | $474.51 | +234% | Bullish | |
| $306.30 | $498.24 | $868.62 | +472% | Bullish | |
| $652.48 | $1,211.22 | $2,322.24 | +12.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $68.45 | $87.04 | $102.24 | +0.00% |
| June 2026 | $75.90 | $89.32 | $107.76 | +2.62% |
| July 2026 | $77.73 | $92.33 | $113.03 | +3.37% |
| August 2026 | $76.73 | $91.81 | $113.67 | -0.56% |
| September 2026 | $77.33 | $93.08 | $116.31 | +1.39% |
| October 2026 | $80.68 | $97.65 | $123.04 | +4.91% |
| November 2026 | $81.13 | $98.68 | $125.24 | +1.05% |
| December 2026 | $79.23 | $96.81 | $123.71 | -1.89% |
Click any year to see its month-by-month DRUG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DRUG to range from $68.45 to $123.71 through 2026. The $87.04 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DRUG price prediction for 2027 points to an average of $107.89 (low $84.76, high $145.96) — a potential gain of +24% on today's $87.04. Momentum favours further upside here.
In 2028, DRUG is projected to trade between $98.08 and $180.91, averaging $128.66 — a potential gain of +48% from today's $87.04. That is up +19% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Bright Minds Biosciences Inc.'s 2029 outlook centres on $141.68, within a $105.31 to $205.37 range. That is up +10% on the projected 2028 average. That marks a +63% change versus current levels. Momentum favours further upside here.
By 2030, DRUG could reach as high as $285.07, with a base case around $191.66 and support toward $139.30 — roughly +120% from $87.04. Buyers look set to stay in control over this stretch.
Expect DRUG to range from $162.77 to $347.78 through 2031. The $228.62 average target implies a +163% move from current prices. That is up +19% on the projected 2030 average. Momentum favours further upside here.
The DRUG price prediction for 2032 points to an average of $236.50 (low $165.17, high $367.09) — a potential gain of +172% on today's $87.04. Buyers look set to stay in control over this stretch.
In 2033, DRUG is projected to trade between $189.17 and $436.01, averaging $275.81 — a potential gain of +217% from today's $87.04. That is up +17% on the projected 2032 average. Momentum favours further upside here.
Bright Minds Biosciences Inc.'s 2034 outlook centres on $282.07, within a $190.15 to $453.48 range. That is up +2% on the projected 2033 average. That marks a +224% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DRUG could reach as high as $474.51, with a base case around $290.58 and support toward $192.67 — roughly +234% from $87.04. Momentum favours further upside here.
Expect DRUG to range from $306.30 to $868.62 through 2040. The $498.24 average target implies a +472% move from current prices. That is up +71% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DRUG price prediction for 2050 points to an average of $1,211.22 (low $652.48, high $2,322.24) — a potential gain of +12.9x on today's $87.04. Momentum favours further upside here.
Investing $1,000 in DRUG today (≈ 11.488971 DRUG) could be worth
$13,915.69
+$12,915.69 (+1292%) by 2050 · US Dollar
Based on the average projected DRUG price of $1,211.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DRUGwould be worth at today's price.
$1,000 invested in DRUG on May 27, 2025 (≈ 36.443148 DRUG) would be worth
$3,172.01
+$2,172.01 (+217.2%) today · 3.17× · US Dollar
Based on a DRUG entry price of $27.44 vs. today's $87.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $82.78 | $1,051.46 | +5.1% |
| 1 month ago | $90.24 | $964.54 | -3.5% |
| 3 months ago | $85.5 | $1,018.01 | +1.8% |
| 6 months ago | $70 | $1,243.43 | +24.3% |
| 1 year ago | $27.44 | $3,172.01 | +217.2% |
| All time (5.0y) ago | $24 | $3,626.67 | +262.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DRUG forecast.
Our base-case forecast reaches $170.00 around 2030.
Implied market cap at $170.00: $1.67B
The multi-year forecast shows a bullish trajectory with rising averages from 2027 onward. The 2027 average is $102.54 with a max of $139.64 and an ROI of 22.8, signaling meaningful upside if the path continues. By 2030 the average is projected to $178.96 with a max of $268.71 and an ROI of 114.3, indicating substantial longer-run upside.
In the 2040 horizon, the average is $446.01 with a max of $788.52 and an ROI of 434.1, while the 2050 horizon shows an average of $1,082.02 with a max of $2,108.87 and an ROI of 1195.8, reflecting strong potential appreciation under favorable conditions. The maximums across the forecast reach higher levels, illustrating significant upside in the longer term.
These are estimates, not guarantees. The forecast reflects market expectations embedded in the numbers provided and should be considered alongside inherent investment uncertainty and risk.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $178.96, a min of $128.96, a max of $268.71, with an ROI of 114.3 and bullish sentiment.
The forecast indicates bullish sentiment from 2027 onward with rising average prices (e.g., 2027 avg $102.54; 2029 avg $131.89; 2030 avg $178.96). The 2026 value is neutral, and the 2050 horizon shows strong upside (avg $1,082.02; max $2,108.87; ROI 1195.8). These are estimates, not guarantees.
Yes. The 2040 forecast max is $788.52, which exceeds $500, with the 2030–2035 years showing smaller maxima (e.g., 2030 max $268.71; 2035 max $433.78).
Current price is $83.50 and market cap is $817.23M. The rank is 2677.
Sentiment is BULLISH. RSI14 is 50. SMA50 is $81.13 and SMA200 is $70.13. Support is $74.54 and resistance is $90.79; the 30-day range is $67.97 to $102.57.
Bright Minds Biosciences Inc. Community Discussion
0Share your Bright Minds Biosciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.